- Home
- SUUN vs ANVS Comparison
SUUN vs ANVS Comparison
Compare SUUN & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SUUN | ANVS |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.2M | 69.1M |
| IPO Year | 2024 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SUUN | ANVS |
|---|---|---|
| Price | $0.63 | $2.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $3.00 | ★ $13.50 |
| AVG Volume (30 Days) | 507.4K | ★ 1.4M |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $112.68 | N/A |
| Revenue Next Year | $1.75 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.45 | $1.44 |
| 52 Week High | $2.55 | $5.50 |
Technical Indicators
Market Signals| Indicator | SUUN | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 48.63 | 59.35 |
| Support Level | $0.45 | $1.92 |
| Resistance Level | $0.70 | $2.67 |
| Average True Range (ATR) | 0.06 | 0.15 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 38.28 | 87.35 |
Price Performance
Historical ComparisonAbout SUUN SolarBank Corporation
PowerBank Corp is an independent renewable and clean energy project developer, power producer, and asset operator in Canada and the United States, with the majority of its revenue coming from the United States. The Company operates through two reportable segments: Development and EPC, which involves the development and construction of solar photovoltaic power projects, and IPP Production, which includes the operation of solar power and battery energy storage systems. Corporate and other activities cover operation, maintenance, and repairs. The majority of revenue is generated from the Development and EPC segment.
About ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.